Protagonist Therapeutics Inc (PTGX)
Working capital turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 434,433 | 60,000 | 26,581 | 27,357 | 28,628 |
Total current assets | US$ in thousands | 591,641 | 355,577 | 237,355 | 340,736 | 315,606 |
Total current liabilities | US$ in thousands | 47,398 | 21,274 | 31,179 | 44,016 | 40,241 |
Working capital turnover | 0.80 | 0.18 | 0.13 | 0.09 | 0.10 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $434,433K ÷ ($591,641K – $47,398K)
= 0.80
The working capital turnover of Protagonist Therapeutics Inc has shown fluctuating trends over the period from 2020 to 2024. In 2020 and 2021, the company's working capital turnover was 0.10 and 0.09 respectively, indicating a relatively inefficient utilization of its working capital to generate sales. However, there was an improvement noted in 2022 with a working capital turnover of 0.13, suggesting a slightly better efficiency in managing its working capital for sales generation.
Notably, there was a significant increase in working capital turnover in 2023, reaching 0.18, which indicates a more effective management of working capital to support sales activities. This positive trend continued in 2024, with a substantial rise in the working capital turnover to 0.80, highlighting a significant improvement in the company's efficiency in converting working capital into sales.
Overall, the increasing trend in working capital turnover from 2020 to 2024 reflects Protagonist Therapeutics Inc's efforts to enhance its working capital management efficiency and optimize its operational performance in generating sales.
Peer comparison
Dec 31, 2024